Bristol-Myers Squibb Reports Consistent Safety, Effectiveness For Rheumatoid Arthritis Trial
Orencia, a selective co-stimulation modulator of T-cell activation.
Bristol-Myers Squibb has announced the results of two Orencia (abatacept) studies at the 2009 Annual European Congress of Rheumatology (EULAR), in Copenhagen, Denmark.
Orencia is a selective co-stimulation modulator of T-cell activation.
The first, a long-term extension (LTE) study, analysed Orencia’s safety and efficacy profile over 7 years of treatment in rheumatoid arthritis (RA) patients, who have had an inadequate response to methotrexate (MTX).
The second study is the AIM (Abatacept in Inadequate responders to Methotrexate) study LTE, which reinforces the long-term safety and efficacy profile of Orencia.
X-ray data from the AIM LTE demonstrated that over five years, Orencia inhibited structural damage progression in the majority of patients on treatment. 45.1% of patients (n=120) assessed at year 5 continued to show no progression in structural damage. 98% of patients who were non-progressors during years 1-4 remained non-progressors at year 5.
Related Insight
Suppliers Directory
Health Protection Agency - Protecting the Health of Everyone in the UK
The Health Protection Agency exists to help protect the health of everyone in the UK with particular emphasis on reducing the impacts of infectious diseases, poisons, chemical and radiation hazards.
Suppliers
Farmalyse - Laboratory Contract Services
Farmalyse is a contract service provider for the pharmaceutical industry, hospitals and the medical device industry offering a full range of laboratory investigation services, quality control testing, analytical method development-validation and comprehensive and customised international services which focus on import, release and supply chain management.
Suppliers
BioBuffer Solutions - Biopharm/Biotech Buffers and Reagents
BioBuffer Solutions is a manufacturer of biological buffers and laboratory reagents intended for use in the biopharm and biotech markets. The staff at BioBuffer Solutions has over 15 years of experience in the manufacturing and quality management of these buffers and reagents. We offer fully traceable custom buffers, reagents and solutions.
Suppliers
American Airlines - Efficient Air Cargo Service for the Pharmaceutical Industry
American Airlines (AA) Cargo provides a safe and reliable service to more than 240 cities in 40 countries across the globe, ideal for transporting valuable pharmaceutical equipment and supplies.
Contract Research & Services > Contract Services > Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Intelligence
Phenom™ G2 pure
Published by Phenom World
White Papers
Reliability From Development to Service.
Published by VITLAB®
White Papers
Polygran ® Series of Roller Compactors
Published by Gerteis
White Papers
Staying Compliant with the Physician Payments Sunshine Act
Published by Alliance Life Sciences Consulting Group, Inc.
White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.